{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:06:35Z","timestamp":1789761995562,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.idnow.2026.105298","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:10:01Z","timestamp":1781201401000},"page":"105298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The environmental impacts and costs of cefotaxime versus ceftriaxone: An example drawn from Paris hospitals"],"prefix":"10.1016","volume":"56","author":[{"given":"Etienne","family":"Rapha\u00ebl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Siorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Sokal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Blez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albane","family":"Degrassat-Th\u00e9as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"R\u00e9veillon-Istin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Lepeule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2026.105298_bb0005","author":"The Shift Project [Internet]"},{"key":"10.1016\/j.idnow.2026.105298_bb0010","author":"Commission m\u00e9dicale d'\u00e9tablissement de l'AP-HP, CHU d'\u00cele-de-France [Internet]"},{"key":"10.1016\/j.idnow.2026.105298_bb0015","author":"France"},{"issue":"5","key":"10.1016\/j.idnow.2026.105298_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01640881","article-title":"Ceftriaxone: in vitro activity against 410 bacterial isolates compared with cefotaxime","volume":"10","author":"Digranes","year":"1982","journal-title":"Infection"},{"issue":"6","key":"10.1016\/j.idnow.2026.105298_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jamda.2018.03.011","article-title":"Antibiotics by subcutaneous route: a safe and efficient alternative","volume":"19","author":"Noriega","year":"2018","journal-title":"J Am Med Dir Assoc"},{"issue":"Suppl. 2","key":"10.1016\/j.idnow.2026.105298_bb0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003495-198700342-00008","article-title":"Pharmacokinetic properties of the cephalosporins","volume":"34","author":"Bergan","year":"1987","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.idnow.2026.105298_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ofid\/ofaa312","article-title":"Switching from ceftriaxone to cefotaxime significantly contributes to reducing the burden of Clostridioides difficile infections","volume":"7","author":"Wendt","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.idnow.2026.105298_bb0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1179\/joc.2011.23.6.341","article-title":"Impact of ceftriaxone De-restriction on the occurrence of ESBL-positive bacterial strains and antibiotic consumption","volume":"23","author":"Skrlin","year":"2011","journal-title":"J Chemother"},{"key":"10.1016\/j.idnow.2026.105298_bb0045","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijid.2021.01.025","article-title":"No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: a pilot study","volume":"104","author":"Pilmis","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.idnow.2026.105298_bb0050","first-page":"1","article-title":"The effects of switching from ceftriaxone to cefotaxime on the occurrence of third-generation cephalosporin-resistant Enterobacterales: a stepped-wedge cluster randomized trial","volume":"54","author":"Bouiller","year":"2024","journal-title":"Infect Dis Now"},{"issue":"4","key":"10.1016\/j.idnow.2026.105298_bb0055","article-title":"Ceftriaxone versus cefotaxime: a scoping review of resistance selection, Clostridioides difficile risk, economic implications and environmental impacts","volume":"56","author":"Rapha\u00ebl","year":"2026","journal-title":"Infect Dis Now."},{"issue":"3","key":"10.1016\/j.idnow.2026.105298_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jac\/dkt403","article-title":"Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime","volume":"69","author":"Grohs","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idnow.2026.105298_bb0065","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00134-018-5079-y","article-title":"A hospital-wide intervention replacing ceftriaxone with cefotaxime to reduce rate of healthcare-associated infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in the intensive care unit","volume":"44","author":"Tan","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.idnow.2026.105298_bb0070","author":"Association of the British Pharmaceutical Industry [Internet]"},{"key":"10.1016\/j.idnow.2026.105298_bb0075","author":"Assistance Publique des H\u00f4pitaux de Paris [Internet]"},{"issue":"11","key":"10.1016\/j.idnow.2026.105298_bb0080","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1111\/bcp.16229","article-title":"MCF classifier: estimating, standardizing, and stratifying medicine carbon footprints, at scale","volume":"90","author":"Taylor","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.idnow.2026.105298_bb0085","author":"La Piti\u00e9 Salp\u00eatri\u00e8re [Internet]"},{"issue":"6","key":"10.1016\/j.idnow.2026.105298_bb0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ijpp\/riab065","article-title":"Impact of a training session for prescribers on the relative prescription of cefotaxime over ceftriaxone in elderly patients","volume":"29","author":"Durand","year":"2021","journal-title":"Int J Pharm Pract"},{"issue":"6","key":"10.1016\/j.idnow.2026.105298_bb0095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2165\/00019053-199508060-00008","article-title":"An Assessment of the Hidden and Total Antibiotic Costs of Four Parenteral Cephalosporins","volume":"8","author":"Smyth","year":"1995","journal-title":"PharmacoEconomics"},{"issue":"4","key":"10.1016\/j.idnow.2026.105298_bb0100","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2165\/00019053-199405040-00002","article-title":"Pharmacoeconomic studies on antibiotics: current controversies","volume":"5","author":"Norrby","year":"1994","journal-title":"PharmacoEconomics"},{"issue":"2","key":"10.1016\/j.idnow.2026.105298_bb0105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s41669-022-00385-9","article-title":"Attributable patient cost of antimicrobial resistance: a prospective parallel cohort study in two public teaching hospitals in Ghana","volume":"7","author":"Otieku","year":"2023","journal-title":"PharmacoEconomics Open"},{"issue":"10","key":"10.1016\/j.idnow.2026.105298_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292273","article-title":"Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study","volume":"18","author":"Ayinde","year":"2023","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.idnow.2026.105298_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0195-6701(96)90122-X","article-title":"Financial burden of hospital-acquired Clostridium difficile infection","volume":"34","author":"Wilcox","year":"1996","journal-title":"J Hosp Infect"},{"issue":"2","key":"10.1016\/j.idnow.2026.105298_bb0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jac\/dkq412","article-title":"Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins","volume":"66","author":"De Kraker","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105298_bb0125","first-page":"424","article-title":"Traitements antibiotiques en \u00e9tablissement de sant\u00e9\u00a0: r\u00e9sultats de l\u2019Enqu\u00eate nationale de pr\u00e9valence 2017, France","volume":"21","author":"Daniau","year":"2020","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"10.1016\/j.idnow.2026.105298_bb0130","author":"Viatris [Internet]"},{"issue":"5","key":"10.1016\/j.idnow.2026.105298_bb0135","first-page":"1781","article-title":"Carbon footprint of direct oral anticoagulants in atrial fibrillation and venous thromboembolism","volume":"111","author":"Chery","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.idnow.2026.105298_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclepro.2024.143576","article-title":"Carbon footprint of oral medicines using hybrid life cycle assessment","volume":"475","author":"Piffoux","year":"2024","journal-title":"J Clean Prod"},{"key":"10.1016\/j.idnow.2026.105298_bb0150","author":"Janusinfo [Internet]"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:16:25Z","timestamp":1789758985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991926000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666991926000552"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105298","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The environmental impacts and costs of cefotaxime versus ceftriaxone: An example drawn from Paris hospitals","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105298"}}